Wells Fargo raised the firm's price target on National Health Investors to $86 from $85 and keeps an Equal Weight rating on the shares. The firm notes the company entered a quiet period in on its NHC lease, and it expects a resolution before Q1 earnings. Based on Wells' analysis and conversations with investors, the firm thinks buy-side estimates may have overstated the FFO impact from a rent reset.
